Home » Stocks » BCRX

BioCryst Pharmaceuticals, Inc. (BCRX)

Stock Price: $4.76 USD 0.10 (2.15%)
Updated November 25, 4:00 PM EST - Market closed
After-hours: $4.78 +0.02 (0.42%) Nov 25, 7:58 PM

Stock Price Chart

Key Info

Market Cap 840.45M
Revenue (ttm) 53.52M
Net Income (ttm) -124.94M
Shares Out 176.57M
EPS (ttm) -0.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 25
Last Price $4.76
Previous Close $4.66
Change ($) 0.10
Change (%) 2.15%
Day's Open 4.72
Day's Range 4.59 - 4.78
Day's Volume 4,493,994
52-Week Range 1.58 - 6.29

More Stats

Market Cap 840.45M
Enterprise Value 775.70M
Earnings Date (est) Feb 24, 2021
Ex-Dividend Date n/a
Shares Outstanding 176.57M
Float 174.17M
EPS (basic) -0.72
EPS (diluted) -0.80
FCF / Share -0.59
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 41.32M
Short Ratio 8.62
Short % of Float 23.73%
Beta 2.91
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 15.70
PB Ratio 22.73
Revenue 53.52M
Operating Income -122.46M
Net Income -124.94M
Free Cash Flow -103.46M
Net Cash 64.76M
Net Cash / Share 0.37
Gross Margin -116.47%
Operating Margin -228.81%
Profit Margin -233.40%
FCF Margin -193.31%
ROA -57.39%
ROE n/a
ROIC -309.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (10)

Buy 8
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$8.61*
(80.88% upside)
Low
4.50
Current: $4.76
High
13.00
Target: 8.61
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue48.8420.6525.1926.3548.2613.6117.3326.2919.6462.38
Revenue Growth136.45%-18%-4.43%-45.39%254.62%-21.48%-34.09%33.85%-68.51%-
Gross Profit44.7320.1823.4823.6546.3613.4917.2326.1619.6462.30
Operating Income-99.46-94.22-57.41-48.61-39.44-45.77-30.72-33.89-49.59-34.36
Net Income-109-101-65.78-55.14-43.02-45.19-30.11-39.08-56.95-33.85
Shares Outstanding11610384.4573.7072.9066.7755.2249.4745.1444.56
Earnings Per Share-0.94-0.98-0.78-0.75-0.59-0.68-0.55-0.79-1.26-0.76
Operating Cash Flow-89.58-92.57-41.14-53.44-13.12-38.55-26.53-37.40-32.25-28.56
Capital Expenditures-0.34-0.37-0.32-5.27-5.12-0.110.02-0.11-0.06-0.33
Free Cash Flow-89.93-92.93-41.46-58.71-18.24-38.66-26.51-37.51-32.31-28.88
Cash & Equivalents13810611856.2053.1872.9238.2135.9142.3454.57
Total Debt84.6561.8254.7253.7230.1830.0030.0030.0030.00-
Net Cash / Debt53.1244.1962.962.4723.0042.928.215.9112.3454.57
Assets17514717889.8512213748.8757.4482.21109
Liabilities13797.6194.4988.2774.6461.2449.9957.8967.4043.94
Book Value38.2549.2483.771.5847.7275.64-1.13-0.4514.8165.50
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name BioCryst Pharmaceuticals, Inc.
Country United States
Employees 140
CEO Jon P. Stonehouse

Stock Information

Ticker Symbol BCRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BCRX
IPO Date March 3, 1994

Description

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in Phase I clinical trials to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Torii Pharmaceutical Company; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.